The Subject Expert Committee (SEC) will meet to review Bharat Biotech's application to remove Covaxin from ‘clinical trial mode’, according to sources.
This means a lot for Bharat Biotech for Covaxin. Covishield by Serum Institute was cleared ‘for emergency use only’ post the company’s third phase clinical trial data was assessed by the SEC.
Now Bharat Biotech has submitted all the data required for the phase-III interim data for SEC’s consideration. And has applied to SEC to remove the tag ‘clinical trial mode’ from Covaxine which it got along with the 'emergency use’ authorisation.
Watch the accompanying video of CNBC-TV18’s Timsy Jaipuria for more details.